ArticleHeart rhythm O22022
Anticoagulation in new-onset postoperative atrial fibrillation: An analysis from the Society of Thoracic Surgeons Adult Cardiac Surgery Database.
Article in Heart rhythm O2, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights From the VITAL-AF Trial.Circulation · 2026Trial
- Bleeding risk assessment in patients with new-onset atrial fibrillation after coronary surgery (reply).European heart journal. Cardiovascular pharmacotherapy · 2026Article
- The anticoagulation dilemma in post-operative atrial fibrillation after cardiac surgery.European heart journal. Cardiovascular pharmacotherapy · 2026Article
- Bleeding risk assessment in patients with new-onset atrial fibrillation after coronary surgery: a proof-of-concept study.European heart journal. Cardiovascular pharmacotherapy · 2026Observational
- Predicting Recurrence and Outcomes After Stressor-Associated Atrial Fibrillation Using ECG-Based Deep Learning.Journal of the American Heart Association · 2026Article
- Outcomes in Early Postoperative Versus Late New-Onset Atrial Fibrillation After Coronary Artery Bypass Grafting.Journal of the American Heart Association · 2025Article
- Stellate ganglion block for preventing postoperative arrhythmias: a protocol for a systematic review and meta-analysis.BMJ open · 2025Article
- Postoperative atrial fibrillation in emergent non-cardiac surgery: Risk factors and outcomes from a ten-year intensive-care unit retrospective study.World journal of critical care medicine · 2025Article
- New-onset atrial fibrillation after coronary surgery and stroke risk: a nationwide cohort study.Heart (British Cardiac Society) · 2024Article
- Recurrence of Atrial Fibrillation in Patients With New-Onset Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting.JAMA network open · 2024Article
- Perioperative stroke.Nature reviews. Disease primers · 2024Review
- Review
- Postoperative atrial fibrillation: from mechanisms to treatment.European heart journal · 2023Review
- Evidence gaps pertaining to high-risk medications: Commentary on anticoagulation in new-onset postoperative atrial fibrillation.Heart rhythm O2 · 2022Article
- Challenging anticoagulation decisions in atrial fibrillation: a narrative review.Therapeutic advances in cardiovascular diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: New-onset postoperative atrial fibrillation (POAF) is the most common complication after cardiac surgery and is associated with increased long-term stroke and mortality. Anticoagulation has been suggested as a potential therapy, but data on safety and efficacy are scant. Objectives: To determine the association between anticoagulation for POAF and long-term outcomes. Methods: Adult patients with POAF after isolated coronary artery bypass surgery (CABG) were identified through the Society of Thoracic Surgeons Adult Cardiac Surgery Database and linked to the Medicare Database. Propensity-matched analyses were performed for all-cause mortality, stroke, myocardial infarction, and major bleeding for patients discharged with or without anticoagulation. Interaction between anticoagulation and CHA Results: Of 38,936 patients, 9861 (25%) were discharged on oral anticoagulation. After propensity score matching, discharge anticoagulation was associated with increased mortality (hazard ratio [HR] 1.16, 95% confidence interval [CI] 1.06-1.26). There was no difference in ischemic stroke between groups (HR 0.97, 95% CI 0.82-1.15), but there was significantly higher bleeding (HR 1.60, 95% CI 1.38-1.85) among those discharged on anticoagulation. Myocardial infarction was lower in the first 30 days for those discharged on anticoagulation, but this effect decreased over time. The incidence of all complications was higher for patients with CHA Conclusion: Anticoagulation is associated with increased mortality after new-onset POAF following CABG. There was no reduction in ischemic stroke among those discharged on anticoagulation regardless of CHA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.